Form 4: BioMarin CEO Alexander Hardy Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
BioMarin Pharmaceutical Inc. CEO Alexander Hardy reported the acquisition of 32,780 shares of common stock and 44,050 stock options on March 15, 2024.
Summary
- On March 15, 2024, Alexander Hardy, CEO of BioMarin Pharmaceutical Inc., acquired 32,780 shares of common stock.
- These shares were acquired at a price of $0.
- Following this transaction, Hardy directly owns 148,151 shares of BioMarin common stock.
- Hardy also acquired 44,050 stock options with an exercise price of $83.87 on the same date.
- These options vest in installments, beginning with 12/48th on March 15, 2025, and then 1/48th on the 15th of each month thereafter, expiring on March 14, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The CEO's acquisition of shares and options could be seen as a slightly positive sign of confidence, but it's not overwhelmingly so.
Positives
- The acquisition of shares and stock options by the CEO could be interpreted as a positive signal, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to executive compensation and holdings, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment due to the CEO's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 03/15/2025 | First vesting date for 12/48th of the stock options. |
| 03/14/2034 | Expiration date of the stock options. |
| 03/19/2024 | Date of signature for the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.